ASCO '14: What's on Tap for Saturday

CHICAGO (TheStreet) -- I've landed in this great Midwestern city to attend and cover American Society of Clinical Oncology (ASCO) annual meeting. I'll be posting stories throughout the weekend and into Monday, so check my landing page on TheStreet for links. I'll be tweeting frequently from the ASCO data presentations, too, so follow me on Twitter at @adamfeuerstein.

I tend to keep my ASCO reporting schedule loose for maximum flexibility, but here's a rough idea of what you'll see and when from companies with a significant presence during Saturday's session.

ASCO media embargoes lift at 7:30 am ET on data from Eli Lilly's  (LLY) ramucirumab phase III study in non-small cell lung cancer (abstract no. LBA8006) and Pharmacyclics (PCYC) and Johnson & Johnson's (JNJ) phase III study comparing Imbruvica to Glaxo's  (GSK) Arzerra in relapsed/refractory chronic lymphocytic leukemia. (The "RESONATE" study, abstract no. LBA7008.)

Both of these studies will be featured at an ASCO media briefing starting Saturday at 9 am ET. The actual Lilly ramucirumab data presentation at ASCO isn't until Monday, while Pharmacyclics' Imbruvica RESONATE data is presented on Tuesday. [Yes, this is confusing, but ASCO's data release policy can get funky at times.]

I'm skipping the ASCO media briefing Saturday morning to attend the dueling oral presentations for the competing T790-mutant lung cancer drugs from AstraZeneca (AZN) and Clovis Oncology (CLVS) , respectively. Those presentations start at 9 am ET, I'll tweet as many slides from the presentations as I can. Much of the AstraZeneca data have been disclosed already, but we'll get a meaningful update on the Clovis drug tomorrow.

The other significant Saturday oral presentations features PD-1 immunotherapy data in kidney cancer from Bristol-Myers Squibb (BMY). Those start at 4 pm ET. 

There is also a lung cancer poster session Saturday afternoon featuring data from Bristol, Ariad Pharma (ARIA) and Merrimack Pharma (MACK). 

Karyopharm  (KPTI) has an oral presentation on selinexor data Saturday, as well.


 

 

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Clovis Up on Priority Review Status for Ovarian Cancer Therapy -- Biotech Mover

Clovis Up on Priority Review Status for Ovarian Cancer Therapy -- Biotech Mover

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition